Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Core Viewpoint - Psyence Biomedical Ltd. has approved its 2026 Financial Strategy and Capital Management Framework, which includes a share repurchase program aimed at enhancing shareholder value and supporting planned clinical and regulatory milestones [1][2][3] Financial Strategy - The Board's decision was based on a comprehensive review of the Company's financial position, capital structure, and market conditions, with the goal of protecting shareholder value and preserving capital [2] - The Board believes the current market price of the Company's common shares does not reflect its underlying value, making share repurchases potentially attractive [3][4] Share Repurchase Program - The approved share repurchase program may be executed over the next six to twelve months, contingent on maintaining sufficient cash to fund clinical and regulatory milestones without impairing operational liquidity [5][6] - The Company is not obligated to repurchase shares, and the timing and amount of any repurchases will depend on market conditions and other relevant factors [6][13] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for mental health needs, and is the first such company to be listed on Nasdaq [7]